Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
7.40-0.09 (-1.20%)
At close: 04:00PM EDT
7.55 +0.15 (+2.03%)
After hours: 07:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
Previous Close7.49
Open7.64
Bid7.37 x 1000
Ask7.70 x 800
Day's Range7.38 - 7.82
52 Week Range6.97 - 11.91
Volume639,426
Avg. Volume451,814
Market Cap457.918M
Beta (5Y Monthly)2.51
PE Ratio (TTM)N/A
EPS (TTM)-2.25
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CMPS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • COMPASS Pathways Plc - American
    SDGR: Lowering target price to $29.00SCHRODINGER INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    COMPASS Pathways appoints Daphne Karydas to its Board of Directors

    LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for c

  • GlobeNewswire

    COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

    LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a new paper in Pyschopharmacology, which showed the results of a retrospective study that evaluates the potential of its AI technologies to support investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The paper was published on

  • GlobeNewswire

    COMPASS Pathways to participate in upcoming September investor conferences

    LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences: Citi’s 18th Annual BioPharma Conference: host investor meetings on September 7, 2023HC Wainwright 25th Annual Global Investment Conference: fireside chat at 3:30pm on September 11, 2023 and host investor meetingsMorgan St

Advertisement
Advertisement